Villoglandular papillary adenocarcinoma of the uterine cervix with immunohistochemical characteristics.
Villoglandular papillary adenocarcinoma of uterine cervix has been recently described and to date fewer than a hundred cases have been reported in the world literature. Here we present a 38-year-old woman who underwent radical hysterectomy combined bilateral pelvic lymphoadenectomy and after 28 months postoperatively no lymph node metastasis and no evidence of recurrent disease ocurred. Immunohistochemically Ki-67 overexpression was detected in the tumour, with no immunoreactivity with p53, estrogen and progesteron receptors and broadly-reactive human papilloma virus including types 6, 11, 16, 18, 31, 33, 42, 51, 52, 56, and 58. In this paper, clinical, macroscopical, microscopical and immunohistochemical characteristics of this tumour are reviewed.
Polat
A
A
Dept. of Pathology, University of Mersin, Faculty of Medicine, Turkey. aysep@yahoo.com
Düsmez
D
D
Pata
O
O
Aydin
O
O
Egilmez
R
R
D000231:Adenocarcinoma, Papillary / Q000378:metabolism / Q000473:pathology* / Q000601:surgery; D000328:Adult; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007044:Hysterectomy; D007124:Immunoenzyme Techniques; D008197:Lymph Node Excision; D027383:Papillomaviridae / Q000276:immunology / Q000378:metabolism / Q000472:pathogenicity; D030361:Papillomavirus Infections / Q000150:complications; D011379:Prognosis; D011960:Receptors, Estrogen / Q000378:metabolism; D011980:Receptors, Progesterone / Q000378:metabolism; D016159:Tumor Suppressor Protein p53 / Q000378:metabolism; D014412:Tumor Virus Infections / Q000150:complications; D002583:Uterine Cervical Neoplasms / Q000378:metabolism / Q000473:pathology* / Q000601:surgery
D011960:Receptors, Estrogen; D011980:Receptors, Progesterone; D016159:Tumor Suppressor Protein p53